Question explored with the scientific record
Aurocylobenzaprine
The short version: cyclobenzaprine (Flexeril) is a muscle relaxant with modest short-term benefit for acute low back pain, but its safety profile includes sedation, serotonin syndrome risk, and QT prolongation at high doses.
The evidence for cyclobenzaprine comes from two industry-funded trials published in 2003, summarized in a 2004 review [15]. In one trial of 238 patients, both 5 mg and 10 mg doses were superior to placebo on patient-rated improvement and relief (p < 0.001), but the two doses did not differ from each other. A second trial of 215 patients found 5 mg effective (p < 0.03) while 2.5 mg was not. The trials lasted only 7 days. No long-term safety data exists in this evidence.
The safety concerns are real. Cyclobenzaprine is chemically related to tricyclic antidepressants, which block HERG potassium channels and can prolong the QT interval [14]. A case report documented serotonin syndrome in a 27-year-old woman who took 50-60 mg of cyclobenzaprine while on escitalopram (Lexapro), requiring intensive care [2]. The drug also causes sedation as its main side effect, which the 2004 review notes is not necessary for efficacy [15].
For fibromyalgia, a meta-analysis of 5 trials with 392 participants found "overall and symptom-specific improvements" with cyclobenzaprine [1], but the same review shows that most fibromyalgia drugs produce only modest pain relief with notable adverse effects. In a German consumer report, amitriptyline (a related tricyclic) ranked 7th in harm among fibromyalgia drugs [1].
| Outcome | Cyclobenzaprine 5 mg | Cyclobenzaprine 10 mg | Placebo |
|---|---|---|---|
| Patient-rated improvement (7 days) | Superior to placebo | Superior to placebo | Baseline |
| Sedation rate | Present but not quantified | Present but not quantified | Lower |
| Serotonin syndrome risk | Documented at overdose with SSRI | Documented at overdose with SSRI | None |
My call: for acute low back pain lasting under a week, the benefit is modest and the risks are real. The drug works, but sedation and drug interactions matter. For fibromyalgia, the evidence is weaker and the risk-benefit is worse. Confidence: moderate for short-term acute use, low for any longer-term use.
Sources used 4
-
Review of pharmacological therapies in fibromyalgia syndrome
Most standard pharmacologic therapies for fibromyalgia syndrome yield only modest pain relief with notable adverse effects, necessitating combined pharmacologic/non-pharmacologic management guided by guidelines rather than chasing a single 'magic bullet'.
DOI: 10.1186/ar4441 -
Serotonin syndrome in a patient taking Lexapro and Flexeril: a case report
This case report describes a 27-year-old female patient who developed serotonin syndrome after taking an overdose of Cyclobenzaprine while on a therapeutic dose of Lexapro, highlighting the need for awareness of potential drug interactions in emergency medicine.
DOI: 10.1016/j.ajem.2008.03.028 -
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin
This study investigates the inhibitory effects of the tricyclic antidepressant doxepin on the HERG potassium channel, revealing significant blockade with implications for QT interval prolongation and cardiac arrhythmia.
DOI: 10.1016/j.bcp.2007.04.024 -
Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone
This 2004 review compares three commonly prescribed muscle relaxants—carisoprodol, cyclobenzaprine hydrochloride, and metaxalone—for acute low back pain, summarizing their clinical trial efficacy and safety, abuse potential, and the limitations of the historical evidence while i…
DOI: 10.1016/j.clinthera.2004.09.008